AusBiotech welcomes the newly appointed members of the independent Health Technology Assessment (HTA) Reform Implementation Advisory Group.
AusBiotech CEO Rebekah Cassidy said Australia’s HTA system is a key enabler to the successful development and commercialisation of medical innovations in Australia, with a whole pipeline approach – from bench to bedside – required to bring more life changing medical innovations to patients.
“We welcome the appointment of Elizabeth de Somer, CEO of Medicines Australia, and Anne Harris, Board Deputy Chair of Medicines Australia and Managing Director of Pfizer Australia and New Zealand, as industry representatives.”
“Both Liz and Anne are highly regarded industry leaders, with decades of experience across international and Australian markets. Their contributions are invaluable in shaping the future of health technology access in Australia.”
“We are also encouraged by the breadth of representation on the Implementation Advisory Group, including clinical and patient expertise.”
AusBiotech looks forward to following the outcomes of the Implementation Advisory Group and the increased access to health technologies for Australian patients.
